A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know – Image for illustrative purposes only (Image credits: Unsplash)
Millions of Medicare beneficiaries grappling with obesity soon could access powerful GLP-1 medications at a fraction of their usual cost. The Centers for Medicare & Medicaid Services announced a pilot program that caps monthly copays at $50 for select weight loss drugs, marking a departure from longstanding restrictions on such treatments. Set to launch on July 1, 2026, this initiative addresses affordability barriers for drugs like Wegovy and Zepbound, which often exceed $600 without coverage.
The GLP-1 Bridge Program at a Glance
Dubbed the Medicare GLP-1 Bridge, the program runs through December 31, 2027, as a short-term measure to test expanded access before any permanent changes. It covers specific formulations: injectable and pill versions of Wegovy, the KwikPen of Zepbound, and the Foundayo pill. These medications, proven effective for substantial weight reduction, come in forms that suit different patient preferences.
Participation hinges on enrollment in a Medicare Part D prescription drug plan, though the coverage bypasses standard plan procedures. A central system managed by CMS contractor Humana handles approvals, streamlining access without requiring doctors to be Medicare providers.
Eligibility Criteria for Beneficiaries
Qualification rests on body mass index and related health conditions. Individuals with a BMI of 35 or higher gain automatic entry. Those with a BMI of 27 or above qualify if they also have comorbidities such as heart disease or prediabetes.
Nearly 40% of American adults fall into clinical obesity with a BMI of 30 or more, per Centers for Disease Control and Prevention data, suggesting a large pool of potential participants among Medicare’s overweight or obese enrollees – estimated at around 14 million in prior analyses.
Navigating the Prior Authorization Process
Doctors submit prescriptions for prior authorization through Humana’s established platform, originally used for another Medicare drug initiative. Approval triggers a flat $50 copay at the pharmacy, unaffected by dosage increases – a key feature since most users require escalating doses to sustain results.
This setup diverges sharply from routine Part D claims. The copay stands alone, excluding contributions to annual deductibles or the $2,100 out-of-pocket maximum. Low-income subsidy recipients, known as Extra Help users, face exclusion, potentially pricing out those on tight budgets accustomed to $5-$10 copays.
Balancing Benefits Against Notable Trade-Offs
Cash prices for these drugs remain steep, ranging from $149 to $699 monthly even with discounts via sites like TrumpRx. The $50 copay delivers predictable relief, especially at higher doses where Wegovy pills hit $299 and Foundayo $349. For the roughly half of GLP-1 users who found costs burdensome – and a quarter who deemed them very difficult – this could open doors previously slammed shut.
Yet challenges persist. Studies indicate weight regain upon discontinuation, aligning with the pilot’s finite timeline. Prescriptions for diabetes, cardiovascular risk, or sleep apnea stay under regular Part D, possibly at higher costs. Existing weight loss users may switch if their doctor attests to initial eligibility, even post-weight loss.
Financial hurdles hit hardest for fixed-income seniors. “Fifty dollars a month sounds like a great deal compared to paying the discounted prices through TrumpRx and these other direct-to-consumer options, but it’s a lot of money for somebody who’s living on a $750-a-month Social Security check,” noted Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF.
The program’s structure also burdens Medicare’s budget heavily, as it subsidizes most drug costs. Experts anticipate billions in added annual spending, with uptake levels dictating the exact figure – details CMS has not yet disclosed publicly.
What Lies Beyond the Pilot’s End?
Originally envisioned as a six-month trial feeding into a insurer-led permanent program, the Bridge extended to 18 months after insufficient insurer buy-in by April. This buys time for data collection and negotiations under the Trump administration’s phased expansion plan.
“There’s no sense right now of the cost of the Bridge model, but it is likely to be billions of dollars a year in additional spending for Medicare,” Cubanski observed. While the extension aids planning, uncertainty looms over 2028 coverage, leaving beneficiaries to weigh short-term gains against potential future gaps.
For Medicare enrollees eyeing GLP-1s, the pilot offers a rare affordability window amid obesity’s toll. Decisions now could hinge on personal health needs, financial realities, and hopes for enduring policy shifts. More details appear in the original reporting by KFF Health News.
